Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a report on Wednesday, February 26th.

Minerva Neurosciences Stock Performance

NERV opened at $1.37 on Thursday. The stock has a market capitalization of $9.58 million, a price-to-earnings ratio of -3.11 and a beta of 0.10. Minerva Neurosciences has a fifty-two week low of $1.26 and a fifty-two week high of $3.69. The company has a fifty day moving average of $1.87 and a 200 day moving average of $2.19.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.49. On average, equities research analysts forecast that Minerva Neurosciences will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Citadel Advisors LLC grew its stake in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,764 shares of the biopharmaceutical company’s stock after acquiring an additional 8,525 shares during the period. Citadel Advisors LLC owned 0.37% of Minerva Neurosciences worth $57,000 at the end of the most recent reporting period. 34.56% of the stock is owned by institutional investors and hedge funds.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.